Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
Abstract Blockade of PD-1/PD-L1 interactions is proving an exciting, durable therapeutic modality in a range of cancers whereby T cells are released from checkpoint inhibition to revive their inherent anti-tumour activity. Here we have studied various ways to model ex vivo T cell function in order t...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/17d4c012af55407c96c408b8c553e796 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:17d4c012af55407c96c408b8c553e796 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:17d4c012af55407c96c408b8c553e7962021-12-02T12:11:34ZEx vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation10.1038/s41598-021-83612-32045-2322https://doaj.org/article/17d4c012af55407c96c408b8c553e7962021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83612-3https://doaj.org/toc/2045-2322Abstract Blockade of PD-1/PD-L1 interactions is proving an exciting, durable therapeutic modality in a range of cancers whereby T cells are released from checkpoint inhibition to revive their inherent anti-tumour activity. Here we have studied various ways to model ex vivo T cell function in order to compare the impact of the clinically utilised anti-PD-1 antibody, pembrolizumab (Keytruda) on the activation of human T cells: focussing on the release of pro-inflammatory IFNγ and anti-inflammatory IL-10 to assess functionality. Firstly, we investigated the actions of pembrolizumab in an acute model of T-cell activation with either immature or mature allogeneic dendritic cells (DCs); pembrolizumab enhanced IFNγ and IL-10 release from purified CD4+ T-cells in the majority of donors with a bias towards pro-inflammatory cytokine release. Next, we modelled the impact of pembrolizumab in settings of more chronic T-cell activation. In a 7-day antigen-specific response to EBV peptides, the presence of pembrolizumab resulted in a relatively modest increase in both IFNγ and IL-10 release. Where pembrolizumab was assessed against long-term stimulated CD4+ cells that had up-regulated the exhaustion markers TIM-3 and PD-1, there was a highly effective enhancement of the otherwise exhausted response to allogeneic DCs with respect to IFNγ production. By contrast, the restoration of IL-10 production was considerably more limited. Finally, to assess a direct clinical relevance we investigated the consequence of PD-1/PD-L1 blockade in the disease setting of dissociated cells from lung and colon carcinomas responding to allogeneic DCs: here, pembrolizumab once more enhanced IFNγ production from the majority of tumour preparations whereas, again, the increase in IL-10 release was modest at best. In conclusion, we have shown that the contribution of PD-1—revealed by using a canonical blocking antibody to interrupt its interaction with PD-L1—to the production of an exemplar pro- and anti-inflammatory cytokine, respectively, depends in magnitude and ratio on the particular stimulation setting and activation status of the target T cell. We have identified a number of in vitro assays with response profiles that mimic features of dissociated cell populations from primary tumours thereby indicating these represent disease-relevant functional assays for the screening of immune checkpoint inhibitors in current and future development. Such in vitro assays may also support patient stratification of those likely to respond to immuno-oncology therapies in the wider population.Alexander RobertsLindsay BentleyTina TangFay StewartChiara PalliniJoel JuvvanapudiGraham R. WallaceAlison J. CooperAaron ScottDavid ThickettSebastian T. LuggHollie BancroftBridget HemmingCharlotte FerrisGerald LangmanAndrew RobinsonJoanne ChapmanBabu NaiduThomas PinkneyGraham S. TaylorKristian BrockZania StamatakiCatherine A. BradyS. John CurnowJohn GordonOmar QureshiNicholas M. BarnesNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Alexander Roberts Lindsay Bentley Tina Tang Fay Stewart Chiara Pallini Joel Juvvanapudi Graham R. Wallace Alison J. Cooper Aaron Scott David Thickett Sebastian T. Lugg Hollie Bancroft Bridget Hemming Charlotte Ferris Gerald Langman Andrew Robinson Joanne Chapman Babu Naidu Thomas Pinkney Graham S. Taylor Kristian Brock Zania Stamataki Catherine A. Brady S. John Curnow John Gordon Omar Qureshi Nicholas M. Barnes Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation |
| description |
Abstract Blockade of PD-1/PD-L1 interactions is proving an exciting, durable therapeutic modality in a range of cancers whereby T cells are released from checkpoint inhibition to revive their inherent anti-tumour activity. Here we have studied various ways to model ex vivo T cell function in order to compare the impact of the clinically utilised anti-PD-1 antibody, pembrolizumab (Keytruda) on the activation of human T cells: focussing on the release of pro-inflammatory IFNγ and anti-inflammatory IL-10 to assess functionality. Firstly, we investigated the actions of pembrolizumab in an acute model of T-cell activation with either immature or mature allogeneic dendritic cells (DCs); pembrolizumab enhanced IFNγ and IL-10 release from purified CD4+ T-cells in the majority of donors with a bias towards pro-inflammatory cytokine release. Next, we modelled the impact of pembrolizumab in settings of more chronic T-cell activation. In a 7-day antigen-specific response to EBV peptides, the presence of pembrolizumab resulted in a relatively modest increase in both IFNγ and IL-10 release. Where pembrolizumab was assessed against long-term stimulated CD4+ cells that had up-regulated the exhaustion markers TIM-3 and PD-1, there was a highly effective enhancement of the otherwise exhausted response to allogeneic DCs with respect to IFNγ production. By contrast, the restoration of IL-10 production was considerably more limited. Finally, to assess a direct clinical relevance we investigated the consequence of PD-1/PD-L1 blockade in the disease setting of dissociated cells from lung and colon carcinomas responding to allogeneic DCs: here, pembrolizumab once more enhanced IFNγ production from the majority of tumour preparations whereas, again, the increase in IL-10 release was modest at best. In conclusion, we have shown that the contribution of PD-1—revealed by using a canonical blocking antibody to interrupt its interaction with PD-L1—to the production of an exemplar pro- and anti-inflammatory cytokine, respectively, depends in magnitude and ratio on the particular stimulation setting and activation status of the target T cell. We have identified a number of in vitro assays with response profiles that mimic features of dissociated cell populations from primary tumours thereby indicating these represent disease-relevant functional assays for the screening of immune checkpoint inhibitors in current and future development. Such in vitro assays may also support patient stratification of those likely to respond to immuno-oncology therapies in the wider population. |
| format |
article |
| author |
Alexander Roberts Lindsay Bentley Tina Tang Fay Stewart Chiara Pallini Joel Juvvanapudi Graham R. Wallace Alison J. Cooper Aaron Scott David Thickett Sebastian T. Lugg Hollie Bancroft Bridget Hemming Charlotte Ferris Gerald Langman Andrew Robinson Joanne Chapman Babu Naidu Thomas Pinkney Graham S. Taylor Kristian Brock Zania Stamataki Catherine A. Brady S. John Curnow John Gordon Omar Qureshi Nicholas M. Barnes |
| author_facet |
Alexander Roberts Lindsay Bentley Tina Tang Fay Stewart Chiara Pallini Joel Juvvanapudi Graham R. Wallace Alison J. Cooper Aaron Scott David Thickett Sebastian T. Lugg Hollie Bancroft Bridget Hemming Charlotte Ferris Gerald Langman Andrew Robinson Joanne Chapman Babu Naidu Thomas Pinkney Graham S. Taylor Kristian Brock Zania Stamataki Catherine A. Brady S. John Curnow John Gordon Omar Qureshi Nicholas M. Barnes |
| author_sort |
Alexander Roberts |
| title |
Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation |
| title_short |
Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation |
| title_full |
Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation |
| title_fullStr |
Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation |
| title_full_unstemmed |
Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation |
| title_sort |
ex vivo modelling of pd-1/pd-l1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of t-cell stimulation |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/17d4c012af55407c96c408b8c553e796 |
| work_keys_str_mv |
AT alexanderroberts exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT lindsaybentley exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT tinatang exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT faystewart exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT chiarapallini exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT joeljuvvanapudi exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT grahamrwallace exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT alisonjcooper exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT aaronscott exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT davidthickett exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT sebastiantlugg exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT holliebancroft exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT bridgethemming exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT charlotteferris exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT geraldlangman exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT andrewrobinson exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT joannechapman exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT babunaidu exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT thomaspinkney exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT grahamstaylor exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT kristianbrock exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT zaniastamataki exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT catherineabrady exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT sjohncurnow exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT johngordon exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT omarqureshi exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation AT nicholasmbarnes exvivomodellingofpd1pdl1immunecheckpointblockadeunderacutechronicandexhaustionlikeconditionsoftcellstimulation |
| _version_ |
1718394615056302080 |